APTITUDE HEALTH®

EPICS

EPICS in Small Cell Lung Cancer (SCLC)

June 29, 2022

Report Contents

EPICS

Meeting Snapshot

EPICS

EPICS

VIRTUAL CLOSED-DOOR ROUNDTABLE

DATE:
June 29, 2022

DISEASE-STATE AND DATA PRESENTATIONS by key experts

INSIGHTS REPORT including postmeeting analyses and actionable recommendations

PANEL: 7 key experts in SCLC in 7 states in the US

SCLC-SPECIFIC DISCUSSIONS on the latest research updates, therapeutic advances, and their application in clinical decision-making

Panel Consisting of 7 US Small Cell Lung Cancer Experts

EPICS



Apar Kishor Ganti, MD
University of Nebraska Medical Center

Joshua K. Sabari, MD
NYU Grossman School of Medicine

Anne Chiang, MD, PhD
Yale School of Medicine

Jyoti Malhotra, MD, MPH
City of Hope, Los Angeles

Nagla Abdel Karim, MD
Augusta University

CHAIR:
Carl M. Gay, MD, PhD
MD Anderson Cancer Center

Alberto Chiappori, MD
Moffitt Cancer Center

APTITUDE HEALTH®

Meeting Agenda

EPICS

Time	Topic	Speaker/Moderator
6.00 PM – 6.05 PM	Welcome and Introductions	Carl M. Gay, MD, PhD
6.05 PM – 6.15 PM	Standards of Care Across the SCLC Treatment Continuum	Nagla Abdel Karim, MD
6.15 PM – 6.30 PM	Key Questions and Topics for Discussion	All Faculty
6.30 PM – 6.35 PM	Key Takeaways	Nagla Abdel Karim, MD
6.35 PM – 6.40 PM	Biomarkers in SCLC	Joshua K. Sabari, MD
6.40 PM – 7.00 PM	Key Questions and Topics for Discussion	All Faculty
7.00 PM – 7.05 PM	Key Takeaways	Joshua K. Sabari, MD
7.05 PM – 7.15 PM	Recent Progress and Emerging Therapies in Second Line and Beyond	Apar Kishor Ganti, MD
7.15 PM – 7.50 PM	Key Questions and Topics for Discussion	All Faculty
7.50 PM – 7.55 PM	Key Takeaways	Apar Kishor Ganti, MD
7.55 PM – 8.00 PM	Summary and Meeting Close	Carl M. Gay, MD, PhD

APTITUDE HEALTH®

EPICS

Standards of Care Across the SCLC Treatment Continuum

Nagla Abdel Karim, MD
Augusta University
Augusta, GA

Phase III SKYSCRAPER-02 Primary Results: Tiragolumab in Combination With Atezolizumab + Etoposide in Patients With Untreated ES-SCLC – Efficacy

EPICS

Charles Rodin, et al. 2022. ASCO LBA8507

STUDY POPULATION (N = 490)

> Phase III trial in ES-SCLC

PRIMARY ENDPOINTS

PFS: Primary Analysis Set

Phase III SKYSCRAPER-02 Primary Results: Tiragolumab in Combination With Atezolizumab + Etoposide in Patients With Untreated ES-SCLC – Safety

EPICS

Charles Rodin, et al. 2022. ASCO LBA8507

OUTCOME

> Grade 3/4 TRAEs occurred in 52.3% of the

SAFETY OVERVIEW

n (%)

Tiragolumab + atezolizumab + CE

Placebo + atezolizumab + CE

SLFN11 Predicted Improved PFS and OS in Veliparib (PARPi) + Temozolomide (TMZ) Combination Cohort

M. Catherine Pietanza, *et al*. J Clin Oncol. 2018;36:2386-2394

EPICS

METHODS (N = 490)

> A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral

OVERALL SURVIVAL

APTITUDE HEALTH®

EPICS

Standards of Care Across the SCLC Treatment Continuum – Discussion of SKYSCRAPER-02

Key Takeaways

Discussion Highlights: Standards of Care Across the SCLC Treatment Continuum

EPICS

RECENT UPDATES AND ADVANCES IN SCLC TREATMENT



APTITUDE HEALTH®

EPICS

Biomarkers in SCLC

Joshua K. Sabari, MD
NYU Grossman School of Medicine
New York, NY

Current State of Biomarkers in SCLC and Immune Checkpoint Inhibitors

EPICS

A SLOW AND ONGOING SEARCH FOR BIOMARKERS

> Despite many years of research, no markers that could help improve

SIGNALING PATHWAYS AND PHYSIOLOGIC DOMAINS IN SCLC

APTITUDE HEALTH®

Subtypes of Small Cell Lung Cancer

EPICS

SCLC Molecular Subtypes Identified by Their Key Transcription Regulator



DLL3-Based Therapeutics

EPICS

DLL3

> Direct transcriptional target of ASCL1. Its highest expression is in the SCLC-A subtype (ASCL1 high)



APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Biomarkers in SCLC

Key Takeaways

Discussion Highlights: Biomarkers in SCLC (1/2)

EPICS

APTITUDE HEALTH®

Discussion Highlights: Biomarkers in SCLC (2/2)

EPICS

APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Recent Progress and Emerging Therapies in Second Line and Beyond

Apar Kishor Ganti, MD
University of Nebraska Medical Center
Omaha, NE

Efficacy and Safety of Lurbinectedin as Second-Line Therapy in Chinese Patients With Small Cell Lung Cancer: Preliminary Results of a Phase 1 Study

EPICS

Cheng Y, et al. 2022. ASCO 8580

STUDY POPULATION

STUDY DESIGN



Efficacy and Safety of Lurbinectedin as Second-Line Therapy in Chinese Patients With Small Cell Lung Cancer: Preliminary Results of a Phase 1 Study

Cheng Y, et al. 2022. ASCO 8580

EPICS

RESULTS – DOSE-EXPANSION ARM

RESULTS – EFFICACY AND CTFI LENGTH



A Phase 1/2 Trial of Lurbinectedin (L) in Combination With Pembrolizumab (P) in Relapsed Small Cell Lung Cancer (SCLC): The LUPER Study

EPICS

Calles A, et al. 2022. ASCO 8581

KEY INCLUSION CRITERIA

RESULTS – SAFETY



APTITUDE HEALTH®

Analysis of Patients With Relapsed Small Cell Lung Cancer (SCLC) Receiving Single-Agent Lurbinectedin in the Phase 3 ATLANTIS Trial

Navarro A, et al. 2022 ASCO #8524

EPICS

TREATMENT

TRIAL OVERVIEW



*CAV, cyclophosphamide, Adriamycin, and vincristine.

ATLANTIS Clinical Trial – the Efficacy and Safety of Single-Agent Lurbinectedin Were Analyzed in a Post-hoc Analysis

Navarro A, et al. 2022 ASCO #8524

EPICS

OUTCOMES

RESULTS – EFFICACY



APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Recent Progress and Emerging Therapies in Second Line and Beyond

Key Takeaways

Discussion Highlights: Lurbinectedin in Second-Line Treatment of SCLC (1/2)

EPICS

MOST EXPERTS VIEW LURBINECTEDIN FAVORABLY AND USE IT IN THEIR PRACTICE DESPITE WHAT THEY CONSIDER TO BE MODEST EFFICACY RESULTS

Discussion Highlights: Lurbinectedin in Second-Line Treatment of SCLC (2/2)

EPICS

TREATMENT SEQUENCING PAST THE FIRST LINE

Discussion Highlights: Other Key Takeaways for the Treatment of SCLC in the Second Line

EPICS

RECENT DEVELOPMENTS IN THE SECOND-LINE TREATMENT FOR SCLC AND POTENTIAL NEW AREAS OF INTEREST